Closing the Quality Loop: Facilitating Improvement in Oncology Practice Through Timely Access to Clinical Performance Indicators

Srigley, John R.; Lankshear, Sara; Brierley, J. B.; McGowan, Thomas; Divaris, Dimitrios X. G.; Yurcan, Marta; Rossi, Robin; Yardley, Tim; King, Mary Jane; Ross, Jillian; Irish, Jonathan C.; McLeod, Robin S.; Sawka, Carol

doi:10.1200/jop.2012.000818

Cited by 49 publications

(48 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…40 The American College of Surgeons Commission on Cancer (ACS-CoC) in concert with the CAP developed checklists that contain all the scientifically validated data elements that are to be reported for cancer specimens. [41][42][43][44] Molecular pathology external quality assessment schemes across Europe score the report as well as the test result, and help to guide and educate laboratories as to what should be included in a report. 2 39 The European Society of Pathology has produced guidance for these schemes that has defined how reports will be marked, and this will drive the response of laboratories.…”

Section: Reporting Molecular Pathology Tests For Cancer Patientsmentioning

confidence: 99%

Guidance for laboratories performing molecular pathology for cancer patients

et al. 2014

View full text Add to dashboard Cite

Molecular testing is becoming an important part of the diagnosis of any patient with cancer. The challenge to laboratories is to meet this need, using reliable methods and processes to ensure that patients receive a timely and accurate report on which their treatment will be based. The aim of this paper is to provide minimum requirements for the management of molecular pathology laboratories. This general guidance should be augmented by the specific guidance available for different tumour types and tests. Preanalytical considerations are important, and careful consideration of the way in which specimens are obtained and reach the laboratory is necessary. Sample receipt and handling follow standard operating procedures, but some alterations may be necessary if molecular testing is to be performed, for instance to control tissue fixation. DNA and RNA extraction can be standardised and should be checked for quality and quantity of output on a regular basis. The choice of analytical method(s) depends on clinical requirements, desired turnaround time, and expertise available. Internal quality control, regular internal audit of the whole testing process, laboratory accreditation, and continual participation in external quality assessment schemes are prerequisites for delivery of a reliable service. A molecular pathology report should accurately convey the information the clinician needs to treat the patient with sufficient information to allow for correct interpretation of the result. Molecular pathology is developing rapidly, and further detailed evidence-based recommendations are required for many of the topics covered here.

show abstract

Section: Reporting Molecular Pathology Tests For Cancer Patientsmentioning

confidence: 99%

Guidance for laboratories performing molecular pathology for cancer patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…20 The eCC model provides a pathway to meet these demands, with efficient and error-free data entry, reporting, and transmission of data elements, and with the ability to produce output that is human readable, efficient to use, and easy to interpret.…”

Section: Discussionmentioning

confidence: 99%

“…The Cancer Care Ontario project has shown that there is high acceptability among pathologists and clinicians 22 and that data are usable for the secondary needs of tumor registries, 20 but there remains room for improvement. For instance, both the Reporting Pathology Protocols project reports [23][24][25] and the Cancer Care Ontario implementation reports 22 suggest that pathologists require more time to complete the reporting task.…”

Section: Cap Ecc History Development and Adoptionmentioning

confidence: 99%

Cancer Biomarkers: The Role of Structured Data Reporting

Simpson

Berman

Foulis

et al. 2015

Archives of Pathology & Laboratory Medicine

View full text Add to dashboard Cite

Context.-The College of American Pathologists has been producing cancer protocols since 1986 to aid pathologists in the diagnosis and reporting of cancer cases. Many pathologists use the included cancer case summaries as templates for dictation/data entry into the final pathology report. These summaries are now available in a computer-readable format with structured data elements for interoperability, packaged as ''electronic cancer checklists.'' Most major vendors of anatomic pathology reporting software support this model.Objectives.-To outline the development and advantages of structured electronic cancer reporting using the electronic cancer checklist model, and to describe its extension to cancer biomarkers and other aspects of cancer reporting.Data Sources.-Peer-reviewed literature and internal records of the College of American Pathologists.Conclusions.-Accurate and usable cancer biomarker data reporting will increasingly depend on initial capture of this information as structured data. This process will support the standardization of data elements and biomarker terminology, enabling the meaningful use of these datasets by pathologists, clinicians, tumor registries, and patients.

show abstract

“…19,20 All parameters of the synoptic pathology report are stored in the PALGA database as separate variables, enabling easy data extraction and analysis of large numbers of pathology reports.…”

Section: Data Extractionmentioning

confidence: 99%

Interlaboratory Variability in the Histologic Grading of Colorectal Adenocarcinomas in a Nationwide Cohort

Kuijpers

Sluijter

Thüsen

et al. 2016

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Differentiation grade of colorectal adenocarcinoma (CRC) is a prognostic factor and important for therapy selection. In patients with stage II colon cancer, poor differentiation is an indication for adjuvant chemotherapy. The variability in daily practice in the grading of CRC was assessed in a nationwide cohort. Using the Dutch Pathology Registry (PALGA), all synoptically reported CRC resections from 2010 to 2013 were identified. Proportions of poorly differentiated (PD) adenocarcinomas were determined and compared between 35 laboratories by univariable and multivariable logistic regression analyses. In total, 11,719 resections of 11,681 patients were included, of which 1427 (12.2%) were PD (range between 35 laboratories: 5.0% to 33.2%). After adjustment for case mix, 4 (11%) laboratories still reported a significantly lower (n=2) or higher (n=2) proportion of PD adenocarcinoma compared with the reference laboratory. Seven of 8 investigated laboratories showed considerable intralaboratory variation between pathologists as well. In a subgroup of 2812 patients (2813 tumors) who could have been eligible for adjuvant chemotherapy solely on the basis of the differentiation grade (stage II colon cancer patients without other high-risk factors [ie, T4, <10 lymph nodes evaluated, perforation, ileus, or angioinvasion]), 258 (9.2%) were PD (range between laboratories: 0% to 22.7%). In this subgroup, 4 laboratories still diagnosed significantly more PD adenocarcinomas after multivariable logistic regression analysis, increasing the number of colon cancer patients eligible for adjuvant therapy. In conclusion, this large nationwide cohort demonstrates considerable interlaboratory and intralaboratory variation in differentiation grading of CRC. Better standardization of grading criteria is needed for optimal determination of prognosis and treatment selection.

show abstract

Closing the Quality Loop: Facilitating Improvement in Oncology Practice Through Timely Access to Clinical Performance Indicators

Cited by 49 publications

References 26 publications

Guidance for laboratories performing molecular pathology for cancer patients

Guidance for laboratories performing molecular pathology for cancer patients

Cancer Biomarkers: The Role of Structured Data Reporting

Interlaboratory Variability in the Histologic Grading of Colorectal Adenocarcinomas in a Nationwide Cohort

Contact Info

Product

Resources

About